Abstract
Background Computerized clinical decision support systems (CDSS) are low-cost, scalable tools with the potential to improve guideline-recommended antihypertensive treatment in primary care. Uncertainty remains about the optimal initial antihypertensive therapy in the settings of real practice.
Methods The Learning Implementation of Guideline-based decision support system for Hypertension Treatment (LIGHT) trial is a pragmatic, cluster-randomized controlled trial of CDSS versus usual care conducted in 100 primary care practices in China. The primary outcome is the proportion of hypertension visits with appropriate (guideline-recommended) antihypertensive treatment. Among patients recruited from primary care practices of the intervention group in the LIGHT trial, we further conducted a sub-study, the LIGHT-ACD trial, to compare the effects of initial antihypertensive therapy by randomizing individual patients to receive different antihypertensive regimens of initial monotherapy or dual therapy. The primary outcome of the sub-study is the absolute change in blood pressure from baseline to 9 months.
Results We hypothesize that the use of CDSS will result in a higher proportion of appropriate antihypertensive treatments being prescribed during visits for hypertension control in the LIGHT trial, and that particular choices of monotherapy or combinations of dual therapy lead to greater blood pressure change in the LIGHT-ACD trial.
Conclusion These nested trials will provide reliable evidence on the effectiveness of CDSS for improving adherence to guidelines for hypertension management in primary care, and data on the effectiveness of different initial antihypertensive regimens for blood pressure reduction.
Registration number LIGHT (NCT03636334) and LIGHT-ACD (NCT03587103).
Competing Interest Statement
Dr. Krumholz works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs; was a recipient of a research grant, through Yale, from Medtronic and the US Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research grant with Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin/Baughman Law Firm for work related to the Cook IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the founder of HugoHealth, a personal health information platform, and co-founder of Refactor Health, an enterprise healthcare AI-augmented data management company. Dr. Jing Li discloses that she is a recipient of research grants from the government of China, through Fuwai Hospital, for research to improve the management of hypertension and blood lipids, and to improve care quality and patient outcomes of cardiovascular disease; is a recipient of research agreements with Amgen, through National Center for Cardiovascular Diseases (NCCD) and Fuwai Hospital, for a multi-centre trial to assess the efficacy and safety of Omecamtiv Mecarbil, and for dyslipidemic patient registration; is a recipient of a research agreement with Sanofi, through Fuwai Hospital, for a multi-centre trial on the effects of sotagliflozin; is a recipient of a research agreement with University of Oxford, through Fuwai Hospital, for a multi-centre trial of empagliflozin; and was a recipient of a research agreement, through NCCD, from AstraZeneca for clinical research methods training.
Clinical Trial
LIGHT (NCT03636334);LIGHT-ACD (NCT03587103)
Funding Statement
This project was supported by the CAMS Innovation Fund for Medical Science (2016-I2M-1-006) and the 111 Project (B16005) from the Ministry of Education of China.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of Fuwai Hospital
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Joint senior authors
Data Availability
No data is available. It is our future plan to share the data of this study. However, we are unable to do so at this time.